Episode Details

This episode examines the September 3, 2026, approval of the LEQEMBI (lecanemab) subcutaneous autoinjector by China's NMPA. We explore how this shift from bi-weekly IV infusions to once-weekly at-home administration impacts Alzheimer's treatment and what the NMPA's use of the Priority Review pathway signals to manufacturers of innovative drug-device combination products seeking access to the Chinese market. Key Questions: - What are the key differences between the new subcutaneous LEQEMBI formulation and the previous intravenous version? - Why did the NMPA grant this application a Priority Review? - What does this approval indicate about the NMPA's stance on innovative drug delivery systems? - How does this decision affect the treatment landscape for early Alzheimer's disease in China? - What precedent does this set for other manufacturers of drug-device combination products? - What specific types of data, like human factors studies, are crucial for NMPA submissions of autoinjectors? - What practical steps should regulatory teams take in response to this approval? Sources: - https://investors.biogen.com/news-releases/news-release-details/leqembir-lecanemab-subcutaneous-formulation-initiation How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, including those with complex drug-device combination products. We help you navigate the NMPA regulatory landscape with services like market access strategy, technical dossier compilation using advanced AI, and local representation in China. Our experts can guide you through the submission process, including leveraging pathways like Priority Review, to get your innovative products to market faster. Visit https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI regulatory tools and global product database at https://pureglobal.ai.